Redhill Biopharma

RDHL

Valor de mercado US$ 4,27 mi

Executing a full strategic portfolio reset, RedHill is now a stronger commercial entity with Rebyota® and Clenpiq®, two established FDA-approved gastrointestinal (GI) brands that generated $37.5 million in 2025 net sales under Ferring Pharmaceuticals ("Ferring"), an advanced late-stage pipeline and a fully-controlled commercial infrastructure with capacity for portfolio expansion TEL AVIV, Israel and RALEIGH, N.C., Sept. 30, 2026 /PRNewswire/ -- RedHill Biopharma Ltd.

Together with the previously announced Talicia® strategic divestiture, the acquisition from Ferring of commercialization rights to two larger, proprietary, established gastrointestinal (GI) FDA-approved drugs that together generated approximately $37.5 million in 2025 net sales, completes a major strategic repositioning of RedHill's commercial GI business The divestiture of Talicia and the acquisition of the new GI products from Ferring create a catalyst for commercial growth through a materially larger GI business under RedHill's control, with a significantly stronger liquidity position and provides additional growth and expansion opportunities Under the terms of the agreement, RedHill obtained the exclusive commercialization rights for an upfront payment to Ferring of $12 million plus potential future milestones and tiered royalties.  The $12 million upfront payment is fully funded through the previously announced $18 million Talicia divestment, with RedHill securing exclusive global and U.S. commercialization rights to Ferring's Rebyota® and Clenpiq®, respectively - two synergistic, revenue-generating, FDA-approved GI drugs Rebyota is a proprietary, first and only single-dose FDA-approved Fecal Microbiota Transplant (FMT for prevention of recurrent C.

Executes a major step in RedHill's strategic roadmap to fundamentally reposition the Company's commercial business toward new and larger product opportunities, revenue growth and an accelerated path toward operational profitability -- Realizes substantial value from RedHill's 70% stake in Talicia, currently held within a shared ownership and economic structure, while immediately creating a stronger liquidity position and fully funding the next major steps in RedHill's transformational commercial expansion -- Under the terms of the agreement, Apotex will pay RedHill an upfront payment of $18 million plus up to an additional $35 million in potential worldwide net sales milestone payments RALEIGH, N.C. and TEL AVIV, Israel, Aug. 31, 2026 /PRNewswire/ -- RedHill Biopharma Ltd.

The number of confirmed Ebola cases and deaths has increased substantially to 3221 cases and 1407 deaths -- Finalization of development next steps and potential partnership discussions ongoing, including with the Emergency Task Force expert group of the African Medicines Agency, the Ugandan Ministry of Health and Mbarara University of Science and Technology (MUST), alongside liaison with the Democratic Republic of Congo (DRC) Scientific Advisory Committee -- Professor Pauline Byakika-Kibwika, Vice Chancellor, MUST: "There is an urgent need for additional therapeutic options, and with an oral formulation, ease of administration, human safety database and supportive data, host-directed antiviral opaganib warrants immediate evaluation as a potential treatment candidate for Bundibugyo ebolavirus (BDBV)"  -- Development of opaganib for Ebola is supported by preclinical and clinical safety and efficacy data from multiple studies, including in combination with direct acting antiviral Veklury® (remdesivir, Gilead Sciences) TEL AVIV, Israel and RALEIGH, N.C., July 28, 2026 /PRNewswire/ -- RedHill Biopharma Ltd.

$6 million upfront with up to approximately $13.4 million of potential aggregate gross proceeds upon the exercise in full of warrants TEL AVIV, Israel and RALEIGH, N.C., June 22, 2026 /PRNewswire/ -- RedHill Biopharma Ltd.

$6 million upfront with up to approximately $13.4 million of potential aggregate gross proceeds upon the exercise in full of warrants TEL AVIV, Israel & RALEIGH, N.C., June 18, 2026 /PRNewswire/ -- RedHill Biopharma Ltd.

The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to opaganib1  for the treatment of neuroblastoma, a type of cancer most commonly affecting babies and young children -- Rare pediatric disease designation provides for a Priority Review Voucher (PRV) subject to certain conditions -- This new designation is in addition to opaganib's current neuroblastoma orphan drug designation, providing for potential benefits such as accelerated development and review times, FDA Prescription Drug User Fee Act (PDUFA) application fee waivers, tax credits and seven-years' marketing exclusivity, if approved -- New preclinical data, presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting, showed positive effects of opaganib as a potential add-on therapy in models of neuroblastoma and triple-negative breast cancer (TNBC) 2 -- The neuroblastoma market is expected to be valued at approximately $3.5 billion in 2032 3 -- Opaganib is a novel, potentially broad acting, oral, small molecule drug with demonstrated safety & efficacy profiles 4 . It is in development for multiple oncology, viral (including Ebola virus disease (EVD)), inflammatory and diabetes and obesity-related indications RALEIGH, N.C.

RALEIGH, N.C. and TEL-AVIV, Israel, June 8, 2026 /PRNewswire/ -- RedHill Biopharma Ltd.

Amid the rapidly evolving Ebola virus disease (EVD) outbreak involving the rare Bundibugyo ebolavirus sub-type, for which there are no approved medications or vaccines, RedHill Biopharma is actively discussing potential collaborations for clinical advancement of opaganib 1 , including the World Health Organization's (WHO) SOLIDARITY CORE clinical trial platform Opaganib EVD rationale (analogous to EVD treatment pathway): Phase 3 clinical antiviral activity (severe COVID-19) showing 2 : 70.2% mortality reduction with opaganib given as add-on to best available standard of care (remdesivir + corticosteroids): 6.98% (n=3/43) opaganib + SoC vs. 23.4% (n=11/47) placebo + SoC (p=0.034)) Improved median time to viral RNA clearance by ≥4 days in opaganib-treated patients (median 10 days vs.

Vancouver, BC, May 26, 2026 (GLOBE NEWSWIRE) -- Bessor Minerals Inc. (TSXV:BST) ("Bessor" or the “Corporation”) announces that, on February 9, 2026, it entered into an agreement (the “Agreement”) with Homegold Resources Ltd. (“Homegold”) and Johan Shearer (“Shearer”), pursuant to which Bessor terminated its option to acquire a 100% interest in the Redhill property, located south of Ashcroft, B.C (the "Redhill Property") in exchange for a 30% ownership interest in the Redhill Property (the “30% Ownership Interest”). Under the Agreement, Shearer and Homegold are at liberty to deal with Bessor's 30% Ownership Interest in the Redhill Property in their sole discretion, without the prior written consent of Bessor and Bessor will be entitled to a 30% share of any gross proceeds from such sale or disposition.